Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages

Anemia is a common feature and complication of chronic kidney disease (CKD). Erythropoiesis-stimulating agents (ESAs) and recombinant human erythropoietin have been used widely in renal anemia treatment. Recently, hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) that may impr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2021-12, Vol.912, p.174583-174583, Article 174583
1. Verfasser:	Mima, Akira
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia - drug therapy Anemia - etiology Anemia - metabolism Animals Basic Helix-Loop-Helix Transcription Factors - chemistry Basic Helix-Loop-Helix Transcription Factors - metabolism Cardiovascular Diseases - chemically induced Chronic kidney disease (CKD) End-stage renal disease Enzyme Inhibitors - adverse effects Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Erythropoiesis-stimulating agents (ESAs) Erythropoietin - adverse effects Erythropoietin - pharmacology Erythropoietin - therapeutic use Hematinics - adverse effects Hematinics - pharmacology Hematinics - therapeutic use Humans Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - metabolism Vascular endothelial growth factor (VEGF)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!